Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial
Authors
Middleton, GBrock, K
Summers, Yvonne J
Connibear, J
Shah, R
Ottensmeier, C
Shaw, P
Ming-Lee, S
Popat, S
Barrie, C
Barone, G
Mant, R
Savage, J
Billingham, L
Affiliation
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKIssue Date
2018
Metadata
Show full item recordCitation
Middleton G, Brock K, Summers Y, Connibear J, Shah R, Ottensmeier C, et al. 1384PD Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial. Ann Oncol. 2018;29(suppl_8):497.Journal
Annals of OncologyDOI
10.1093/annonc/mdy292.007Additional Links
https://dx.doi.org/10.1093/annonc/mdy292.007Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy292.007